RKDA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RKDA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Arcadia Biosciences's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcadia Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Arcadia Biosciences Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Packaged Foods subindustry, Arcadia Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Arcadia Biosciences's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Arcadia Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 is calculated as:
For example, Arcadia Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2024 (Change) | * | Current CPI (Dec. 2024) |
= | -1.618 | / | 133.1571 | * | 133.1571 | |
= | -1.618 |
Current CPI (Dec. 2024) = 133.1571.
Arcadia Biosciences Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201503 | -54.271 | 99.621 | -72.541 |
201506 | -133.333 | 100.684 | -176.336 |
201509 | -84.327 | 100.392 | -111.849 |
201512 | -73.036 | 99.792 | -97.455 |
201603 | -90.764 | 100.470 | -120.293 |
201606 | -73.691 | 101.688 | -96.496 |
201609 | -71.909 | 101.861 | -94.003 |
201612 | -76.536 | 101.863 | -100.049 |
201703 | -83.400 | 102.862 | -107.963 |
201706 | -82.792 | 103.349 | -106.671 |
201709 | -44.981 | 104.136 | -57.517 |
201712 | -50.660 | 104.011 | -64.856 |
201803 | -48.182 | 105.290 | -60.935 |
201806 | -52.241 | 106.317 | -65.430 |
201809 | -33.941 | 106.507 | -42.434 |
201812 | -23.800 | 105.998 | -29.898 |
201903 | -34.092 | 107.251 | -42.327 |
201906 | -37.198 | 108.070 | -45.833 |
201909 | -24.828 | 108.329 | -30.518 |
201912 | -25.857 | 108.420 | -31.757 |
202003 | -46.304 | 108.902 | -56.617 |
202006 | -35.403 | 108.767 | -43.342 |
202009 | -26.896 | 109.815 | -32.613 |
202012 | -25.353 | 109.897 | -30.719 |
202103 | -10.908 | 111.754 | -12.997 |
202106 | -11.877 | 114.631 | -13.796 |
202109 | -15.296 | 115.734 | -17.599 |
202112 | -12.159 | 117.630 | -13.764 |
202203 | -8.874 | 121.301 | -9.741 |
202206 | -6.074 | 125.017 | -6.470 |
202209 | -5.490 | 125.227 | -5.838 |
202212 | -3.534 | 125.222 | -3.758 |
202303 | -4.012 | 127.348 | -4.195 |
202306 | -3.533 | 128.729 | -3.655 |
202309 | -2.121 | 129.860 | -2.175 |
202312 | -3.043 | 129.419 | -3.131 |
202403 | -2.366 | 131.776 | -2.391 |
202406 | -1.804 | 132.554 | -1.812 |
202409 | -1.284 | 133.029 | -1.285 |
202412 | -1.618 | 133.157 | -1.618 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Arcadia Biosciences (NAS:RKDA) Cyclically Adjusted Price-to-FCF Explanation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Arcadia Biosciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas J. Schaefer | officer: Chief Financial Officer | 202 COUSTEAU PLACE STE 105, DAVIS CA 95618 |
Stanley Jr Jacot | officer: Chief Executive Officer | 202 COUSTEAU PLACE STE 105, DAVIS CA 95618 |
Pamela Haley | officer: Chief Financial Officer | 202 COUSTEAU PLACE, DAVIS CA 95618 |
Laura Pitlik | officer: Chief Marketing Officer | 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618 |
Chris Cuvelier | officer: Chief Growth Officer | 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618 |
Deborah D Carosella | director | 3603 HAVEN AVE, SUITE E, MENLO PARK CA 94025 |
Matthew T Plavan | officer: Chief Financial Officer | C/O THERMOGENESIS CORP., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742 |
Randall Shultz | officer: Chief Technology Officer | 4222 E. THOMAS ROAD, SUITE 320, PHOEBIIX AZ 85018 |
Sarah Reiter | officer: Chief Commercial Officer | 202 COUSTEAU PLACE, DAVIS CA 95618 |
Lilian Shackelford Murray | director | 228 BEACH ROAD, BELVEDERE CA 94920 |
Kevin Comcowich | director | C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618 |
Albert D. Bolles | director | CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102 |
Eric J. Rey | director, officer: President and CEO | ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618 |
Zhongjin Lu | officer: VP Product Development | ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618 |
Amy Yoder | director | C/O SPECTRUM BRANDS, INC., 6 CONCOURSE PARKWAY, SUITE 3300, ATLANTA GA 30328 |
From GuruFocus
By Business Wire • 07-09-2024
By Business Wire • 03-20-2025
By GuruFocus News • 11-13-2024
By Business Wire • 12-11-2024
By Business Wire • 05-16-2024
By PRNewswire • 12-09-2024
By Business Wire • 07-30-2024
By GuruFocus News • 03-21-2025
By GuruFocus Research • 08-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.